Patents Assigned to Plus Chemicals SA
  • Solid state forms of cabazitaxel and processes for preparation thereof
    Patent number: 8921411
    Abstract: The invention relates to solid state forms of Cabazitaxel, and processes for preparation, via novel synthetic intermediates, thereof, and formulations comprising one or more of the solid state forms of Cabazitaxel. The present invention further provides pharmaceutical compositions comprising one or more of the solid state forms of Cabazitaxel, and a method of treating hormone-refractory prostate cancer.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: December 30, 2014
    Assignee: Plus Chemicals SA
    Inventors: Ondrej Simo, Pavel Vraspir, Tomas Holas, Alexandr Jegorov, Roman Gabriel
  • SOLID STATE FORMS OF CABAZITAXEL AND PROCESSES FOR PREPARATION THEREOF
    Publication number: 20140011865
    Abstract: The invention relates to solid state forms of Cabazitaxel, and processes for preparation, via novel synthetic intermediates, thereof, and formulations comprising one or more of the solid state forms of Cabazitaxel. The present invention further provides pharmaceutical compositions comprising one or more of the solid state forms of Cabazitaxel, and a method of treating hormone-refractory prostate cancer.
    Type: Application
    Filed: July 1, 2013
    Publication date: January 9, 2014
    Applicant: PLUS CHEMICALS SA
    Inventors: Ondrej SIMO, Pavel Vraspir, Tomas Holas, Alexandr Jegorov, Roman Gabriel
  • Polymorphs of fluticasone furoate and process for preparation thereof
    Patent number: 8148353
    Abstract: Provided are polymorphs of fluticasone furoate and processes for preparation thereof.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: April 3, 2012
    Assignee: Plus Chemicals SA
    Inventors: Peter Lindsay MacDonald, Pierluigi Rossetto, Adrienne Kovacsne-Mezei, Roman Gabriel, Alexandr Jegorov, Jiri Faustmann
  • Method of manufacturing of 7-ethyl-10-hydroxycamptothecin
    Patent number: 8039626
    Abstract: The method of manufacturing of 7-ethyl-10-hydroxycamptothecin of formula I characterized in that 7-ethyl-1,2,6,7-tetrahydrocampotothecin of formula IV is oxidized with an oxidizing agent selected from the group comprising iodosobenzene, an ester of iodosobenzene, sodium periodate, potassium periodate, potassium peroxodisulfate and ammonium peroxodisulfate, in a solvent formed by a saturated aliphatic monocarboxylic add containing 1 to 3 carbon atoms, and in the presence of water.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: October 18, 2011
    Assignee: Plus Chemicals SA
    Inventor: Petr Dobrovolny
  • PROCESS FOR THE PREPARATION OF N-PROTECTED-DECYLAMINOETHANAL
    Publication number: 20110009596
    Abstract: Compounds useful in the preparation of telavancin, for example, were prepared. These compounds include decylaminoethanal dialkyl acetals and N-protected decylaminoethanal dialkyl acetals, imidazolidine derivatives, and N-protected-decylaminoethanal.
    Type: Application
    Filed: July 8, 2010
    Publication date: January 13, 2011
    Applicant: Plus Chemicals SA
    Inventors: Ettore Bigatti, Deborah Bollini, Augusto Canavesi, Ondrej Simo
  • CRYSTALLINE FORMS OF ERLOTINIB BASE AND ERLOTINIB HCL
    Publication number: 20100004449
    Abstract: The preparation of crystalline Erlotinib base form G2 is described. This crystalline form can be converted to an Erlotinib salt, such as Erlotinib HCl, which can be used in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
    Type: Application
    Filed: July 7, 2009
    Publication date: January 7, 2010
    Applicant: PLUS CHEMICALS SA
    Inventors: Ales GAVENDA, Pavel VRASPIR, Augusto CANAVESI, Judith ARONHIME, Ettore BIGATTI, Jiri FAUSTMANN, Alexandr JEGOROV, Peter W. STEPHENS, Giovanna LUX, Maurizio PAIOCCHI